Long Ideas - Investors in Ziopharm Oncology (ZIOP) eagerly await the release of top-line data from the phase 3 trial, PICASSO III, of Palifosfamide in first-line metastatic Soft … Continue Reading
Read nowLong Ideas - Shares of ISIS Pharmaceuticals (ISIS) were up over 8% at the close of trading on Monday, just days ahead of the American Association of Neurology … Continue Reading
Read nowLong Ideas - With the approval of Kynamro, we believe that Isis Pharmaceuticals (NASDAQ:ISIS) is a compelling long-term investment due to it’s additional pipeline candidates, multiple drug development … Continue Reading
Read nowLong Ideas - InterMune (NASDAQ:ITMN) just announced very favorable pricing on their latest round of financing. The company sold $105 million aggregate principal amount of its 2.5% senior … Continue Reading
Read now